Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  "histone deacetylase"
Results 1-25 of 92 for your search:
Start Over
Radiation Therapy and Romidepsin with or without Poly ICLC in Treating Patients with Previously Treated Stage IIA-IVA Mycosis Fungoides
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S13-00686, NCI-2014-00279, i13-00686, NYU S13-00686, NCT02061449
Vorinostat and Hydroxychloroquine in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTRC 08-52, NCI-2012-01694, HSC20080462H, NCT01023737
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-078, NCI-2011-02511, CDR0000689900, NCT01249443
ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-ST-201, NCI-2015-01870, NCT02551185
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SNDX-275-0602, NCI-2016-01257, NCT02708680
Ruxolitinib Phosphate and Pracinostat in Treating Patients with Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0445, NCI-2015-00002, NCT02267278
Vorinostat in Treating Patients with Metastatic Melanoma of the Eye
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO5917, NCI-2012-00860, CUMC-IRBAAAO5917, MSKCC-12-027, 9111, 12-027, NCT01587352
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
Mocetinostat in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma or Follicular Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-106, NCI-2014-02289, NCT02282358
Vorinostat and Hydroxychloroquine or Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CTMS 14-2015, NCI-2015-00203, NCI-2015-00175, 2015, HSC20150178H, 14-2015, NCT02316340
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients with Relapsed Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-15004, NCI-2015-01557, PO-CL-MM-PI-003687, 20151967, 2015W0166, NCT02569320
Ricolinostat and Ibrutinib or Idelalisib in Treating Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-558, NCI-2016-01352, NCT02787369
Lenalidomide and Romidepsin with or without Dexamethasone in Treating Patients with Recurrent or Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma, or Multiple Myeloma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 1112009392, NCI-2015-00921, NCT01742793
Romidepsin and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Stage IB-IVB Relapsed or Refractory T-cell Lymphomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 112516, NCI-2014-01722, CC#112516, NCT01902225
Azacitidine and Entinostat Followed by Nivolumab or Nivolumab Alone in Treating Patients with Recurrent Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: J1353, NCI-2013-02334, NA_00084192/CIR00003289, NA_00084192, NCT01928576
Panobinostat, Lenalidomide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-262, NCI-2013-02008, CLBH589BUS82T, NCT01965353
Ixazomib, Panobinostat, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 4A13, NCI-2014-00228, NCI-2014-00267, CLBH589DUS92T, US92T, NCT02057640
Exemestane with or without Entinostat in Treating Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Romidepsin and Lenalidomide in Treating Patients with Previously Untreated Peripheral T-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H04, NCI-2014-01770, RV-CL-PTCL-PI-003974, STU00097620, NCT02232516
Sorafenib Tosylate, Vorinostat, Gemcitabine Hydrochloride, and Radiation Therapy in Treating Patients with Pancreatic Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-12-07328, NCI-2015-00017, NCT02349867
Panobinostat, Bortezomib, and Vincristine Sulfate Liposome with Re-induction Therapy in Treating Younger Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: TSALV, NCI-2015-00935, NCT02518750
Pembrolizumab and Vorinostat in Treating Patients with Stage IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18494, NCI-2016-00309, NCT02638090
Paclitaxel and Ricolinostat in Treating Patients with Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-483, NCI-2016-00503, NCT02661815
HDAC Inhibitor AR-42 and Pazopanib Hydrochloride in Treating Patients with Advanced Soft Tissue or Kidney Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-14-10774, NCI-2016-00851, NCT02795819
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with Unresectable or Metastatic Cholangiocarcinoma
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1542, NCI-2016-01057, NCT02856568
Start Over